Year None20222021202020192018201720162015 Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis October 3, 2022 at 4:01 PM EDT Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 September 29, 2022 at 4:05 PM EDT Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 2, 2022 at 4:30 PM EDT Kezar Life Sciences to Participate in Three Upcoming Investor Conferences September 1, 2022 at 7:00 AM EDT Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update August 11, 2022 at 4:01 PM EDT Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 3, 2022 at 4:30 PM EDT Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position July 11, 2022 at 4:30 PM EDT Kezar Life Sciences to Present at the William Blair Biotech Focus Conference July 7, 2022 at 4:30 PM EDT Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) July 6, 2022 at 4:30 PM EDT Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis June 27, 2022 at 4:01 PM EDT Pagination Current page 1 Page 2 Next page next › Last page last »
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis October 3, 2022 at 4:01 PM EDT
Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American College of Rheumatology Convergence 2022 September 29, 2022 at 4:05 PM EDT
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) September 2, 2022 at 4:30 PM EDT
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences September 1, 2022 at 7:00 AM EDT
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update August 11, 2022 at 4:01 PM EDT
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position July 11, 2022 at 4:30 PM EDT
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference July 7, 2022 at 4:30 PM EDT
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis June 27, 2022 at 4:01 PM EDT